Our Vision
Our vision is to be a leader in identifying, developing and commercializing novel drugs that address unmet needs of people with rare cancer conditions.
Learn more about us:
Ascelia Pharma Company Introduction – October 2024
TOP STORIES
Quarterly Report Q3: Successful Outcome from Rights Issue with SEK 105 Million Extends Runway Until Late 2025
2024-11-07 07:30:00
Ascelia Pharma AB (publ) (ticker: ACE) today published its Interim Report Q3 for 2024 (January – September), which is now available on the company’s website: https://www.ascelia.com/ir-med …
TOP STORIES
Ascelia Pharma Announces Completion of Full Study Report Reinforcing the Successful Outcomes of Orviglance Phase 3 Study SPARKLE
2024-11-06
Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced the completion of the Full Study Report for […]
TOP STORIES
Bulletin from the Extraordinary General Meeting in Ascelia Pharma AB on 30 October 2024
2024-10-30 14:45:00
Today, on 30 October 2024, an extraordinary general meeting was held in Ascelia Pharma AB. A summary of the adopted resolutions follows below. Election of new board member and remuneration […]
Upcoming Events
Latest News
Presentations & Articles
INVESTOR
Shortcut to our latest Financial Reports
Key downloads
Quarterly Report Q3: Successful Outcome from Rights Issue with SEK 105 Million Extends Runway Until Late 2025Half-Year Report 2024: Orviglance Completes Clinical Development with Successful Phase 3 StudyQuarterly Report Q1: Primary Endpoint Met with Strong Headline Results in Orviglance Phase 3 StudyAnnual Report 2023: Solid Progress with Orviglance Phase 3 Patient Recruitment Completed and Headline Results Expected by May 2024Q4 and Full Year Report 2023: Strengthened Financial Position Ahead of SPARKLE Phase 3 Study Headline Results in May